# AstraZeneca PLC (AZN) — Stock CV

AstraZeneca PLC is a $247B healthcare company. Revenue grew 8.6% over the last year, it keeps 17¢ of every dollar of sales as profit, and its net debt equals ~2.6 years of free cash flow. It trades at 23.4× earnings — around the middle of its own history.

> A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999.

## Identity

- **Ticker**: AZN
- **Sector**: Healthcare
- **Industry**: Drug Manufacturers - General
- **Employees**: 96 100
- **Website**: https://www.astrazeneca.com
- **Market cap**: $247B
- **Last price**: $159.20
- **Financial profile**: Solid

## Vitals (FY2025)

- **Revenue**: $58.7B
- **Net income**: $10.2B
- **Free cash flow**: $10.7B
- **Net debt**: $27.4B
- **P/E**: 23.4
- **Revenue growth (YoY)**: 8.6%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 72 |
| Growth | 95 |
| Profitability | 72 |
| Health | 61 |
| Quality | 85 |
| Moat | 68 |

## Qualifications (beginner checklist) — 11 of 11 passed

- [x] Revenue growing — +8.6% YoY
- [x] Profitable — $10.2B FY2025
- [x] Profit growing — +45.9% YoY
- [x] Generates cash — $10.7B FY2025
- [x] Debt under control — ~2.6y of cash flow to repay
- [x] Established company — $247B market cap
- [x] Not printing shares — +0.1% shares over ~5y
- [x] Proven track record — 5/5 profitable years
- [x] Financially stable — Altman Z 2.2 — grey
- [x] Pays a dividend — yield 2.01%
- [x] Valuation not extreme — P/E 23.4

## Experience (career milestones)

- **2026** — AstraZeneca held talks with Bristol Myers Squibb over a potential merger worth nearly $400 billion,…
- **FY2025** — Best year on record: $10.2B net income
- **2025** — AstraZeneca announced the acquisition of Belgian biotech company EsoBiotec for up to $1 billion to…
- **FY2024** — Revenue crossed $50B: $54.1B for the year
- **FY2021** — Profitable every year on record: 5 consecutive profitable years in our data
- **FY2021** — Revenue already above $10B: $37.4B in first reported year
- **FY2021** — Positive free cash flow every year since: 5-year streak
- **2020** — AstraZeneca made a preliminary approach to Gilead Sciences about a potential merger, worth almost…
- **2014** — The company entered into a deal with Almirall to acquire its subsidiary Almirall Sofotec and its lung…
- **2012** — Then in April 2012, AstraZeneca acquired Ardea Biosciences, another biotechnology company, for $1.26 billion
- **2011** — AstraZeneca acquired Guangdong BeiKang Pharmaceutical Company, a Chinese generics business
- **2009** — AstraZeneca acquired Novexel Corp, an antibiotics discovery company formed in 2004 as a spin-off…
- **2007** — AstraZeneca's pipeline, and "patent cliff", was the subject of much speculation in April 2007 leading to…
- **2006** — Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate…
- **1913** — Astra AB was founded in 1913 in Södertälje, Sweden, by 400 doctors and apothecaries

## Strengths

- High gross margin (81.3%)
- Strong cash conversion — FCF is 18.2% of revenue
- Interest covered 12.7× by operating earnings

## Watch-outs

- None stand out in the data.

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $37.4B | $112M | $8.72B |
| FY2022 | $44.4B | $3.29B | $8.98B |
| FY2023 | $45.8B | $5.96B | $9.94B |
| FY2024 | $54.1B | $7.04B | $11.8B |
| FY2025 | $58.7B | $10.2B | $10.7B |

---

Source: https://stockcv.com/AZN — derived from company filings; may be delayed or incomplete. Information, not investment advice.